Constitution of ex Vivo Ovarian Tumor Models for the Validation of the Interest of Innovative Therapies and the Search for Tumor or Circulating Biomarkers Predictive of Treatment Response

NCT03831230 | Completed

• 1 other identifier: 2018-A02152-53
• Study Type: observational
• Target: 250
• Locations: 1 country
• Sites: 1

Brief Summary

Development of ex vivo models of ovarian cancer, fallopian tubes or peritoneum.

Conditions

Ovarian Cancer

Keywords

ex vivo; predictive tests; tumor models

Outcome Measures

Primary Outcomes (1)

• Rates of exploitable ex vivo tumor, blood and urine samples for performing predictive tests

  Number and quality of tumor, blood and urine samples that can be used to perform predictive tests of the response to treatment

  Collection of blood, urine, tumor and ascite samples at the time of ovarian surgery

Interventions

collection of blood, urine, tumor and ascite samples GENETIC

collection of blood, urine, tumor and ascite samples during ovarian surgery

Eligibility Criteria

• Age: 18 Years+
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

Patient with ovarian cancer, carcinoma of the fallopian tubes, or histologically proven peritoneum. All FIGO stages are accepted for the study.

You may qualify if:

• Patient over 18 years old.
• Patient with ovarian cancer, carcinoma of the fallopian tubes, or histologically proven peritoneum. All FIGO stages are accepted for the study.
• Patient to be managed by surgery (laparoscopy and / or laparotomy).

You may not qualify if:

• Pregnant woman
• Persons deprived of liberty or guardianship (including curatorship)

Sponsors & Collaborators

• Centre Francois Baclesse: lead

Study Sites (1)

Centre François BACLESSE

Caen, France

Location

Related Publications (1)

• Thorel L, Divoux J, Lequesne J, Babin G, Morice PM, Florent R, Desmartin G, Lecouflet L, Marde Alagama C, Leconte A, Clarisse B, Briand M, Rouzier R, Gaichies L, Martin-Francoise S, Le Brun JF, Denoyelle C, Vigneron N, Jeanne C, Blanc-Fournier C, Leman R, Vaur D, Figeac M, Meryet-Figuiere M, Joly F, Weiswald LB, Poulain L, Dolivet E. The OVAREX study: Establishment of ex vivo ovarian cancer models to validate innovative therapies and to identify predictive biomarkers. BMC Cancer. 2024 Jun 7;24(1):701. doi: 10.1186/s12885-024-12429-w.

  PMID: 38849726 DERIVED

MeSH Terms

Conditions

Ovarian Neoplasms

Interventions

Urination; Tumor Burden

Condition Hierarchy (Ancestors)

Endocrine Gland Neoplasms; Neoplasms by Site; Neoplasms; Ovarian Diseases; Adnexal Diseases; Genital Diseases, Female; Female Urogenital Diseases; Female Urogenital Diseases and Pregnancy Complications; Urogenital Diseases; Genital Neoplasms, Female; Urogenital Neoplasms; Genital Diseases; Endocrine System Diseases; Gonadal Disorders

Intervention Hierarchy (Ancestors)

Urinary Tract Physiological Phenomena; Reproductive and Urinary Physiological Phenomena; Body Weights and Measures; Anthropometry; Investigative Techniques

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: PROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: January 28, 2019
• First Posted: February 5, 2019
• Study Start: March 7, 2019
• Primary Completion: February 27, 2025
• Study Completion: February 27, 2025
• Last Updated: August 8, 2025

Record last verified: 2025-08

Locations

FR (1)